Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4325284 | 0.81 | CCR2 (0.44) | CYP4F2CYP4A11CCR2IDH1DPP4 | |
| SCHEMBL13246788 | 0.78 | CCR2 (0.47) | CCR2IDH1DPP4FAPDPP7 | |
| SCHEMBL1555946 | 0.78 | CYP4F2 (0.52) | CYP4F2CYP4A11SPHK1CTSSCTSK | |
| SCHEMBL26699654 | 0.78 | CYP4F2 (0.38) | CYP4F2CYP4A11CTSK | |
| SCHEMBL13246789 | 0.77 | CCR2 (0.46) | CCR2IDH1DPP4FAPDPP7 | |
| SCHEMBL7184587 | 0.76 | CYP4F2 (0.35) | CYP4F2CYP4A11 | |
| SCHEMBL15177359 | 0.75 | CCR2 (0.44) | CCR2IDH1DPP4FAPDPP7 | |
| SCHEMBL836834 | 0.75 | CCR2 (0.44) | CYP4F2CYP4A11CCR2IDH1DPP4 | |
| Methylamine SCHEMBL6804391 | 0.75 | CYP4F2 (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL9652423 | 0.74 | CCR2 (0.43) | CCR2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10786479-B2 | Methods for inhibiting conversion of carnitine to trimethylamine (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2020-09-29 | — | — | US | disclosed |
| US-10780072-B2 | Methods for inhibiting conversion of choline to trimethylamine (TMA) | THE PROCTER & GAMBLE COMPANY (US) | 2020-09-22 | — | — | US | disclosed |
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | disclosed |
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | disclosed |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | disclosed |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | THE CLEVELAND CLINIC FOUNDATION | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151208-A1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | HNMT, BHMT, PNMT | CYP4F2 667/4885CYP4A11 520/4885CCR2 4077/4885 |
| US-10780072-B2 | Methods for inhibiting conversion of choline to trimethylamine (TMA) | HNMT, BHMT, PNMT | CYP4F2 667/4885CYP4A11 520/4885CCR2 4077/4885 |
| US-10786479-B2 | Methods for inhibiting conversion of carnitine to trimethylamine (TMA) | CRAT, CPT1A, CPT1B | CYP4F2 613/4885CYP4A11 887/4885CCR2 3610/4885 |
| US-20170151250-A1 | METHODS FOR INHIBITING CONVERSION OF CARNITINE TO TRIMETHYLAMINE (TMA) | CRAT, CPT1A, CPT1B | CYP4F2 613/4885CYP4A11 887/4885CCR2 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.